Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Preferred Stock Liabilities (2016 - 2019)

Historic Preferred Stock Liabilities for United Therapeutics (UTHR) over the last 8 years, with Q2 2019 value amounting to $8.4 million.

  • United Therapeutics' Preferred Stock Liabilities fell 5625.0% to $8.4 million in Q2 2019 from the same period last year, while for Jun 2019 it was $8.4 million, marking a year-over-year decrease of 5625.0%. This contributed to the annual value of $19.2 million for FY2018, which is 0.0% changed from last year.
  • United Therapeutics' Preferred Stock Liabilities amounted to $8.4 million in Q2 2019, which was down 5625.0% from $19.2 million recorded in Q1 2019.
  • In the past 5 years, United Therapeutics' Preferred Stock Liabilities registered a high of $20.4 million during Q1 2015, and its lowest value of $8.4 million during Q2 2019.
  • Its 5-year average for Preferred Stock Liabilities is $15.2 million, with a median of $16.1 million in 2015.
  • As far as peak fluctuations go, United Therapeutics' Preferred Stock Liabilities tumbled by 6659.69% in 2015, and later skyrocketed by 7614.68% in 2017.
  • Over the past 5 years, United Therapeutics' Preferred Stock Liabilities (Quarter) stood at $11.1 million in 2015, then fell by 1.8% to $10.9 million in 2016, then skyrocketed by 76.15% to $19.2 million in 2017, then changed by 0.0% to $19.2 million in 2018, then plummeted by 56.25% to $8.4 million in 2019.
  • Its last three reported values are $8.4 million in Q2 2019, $19.2 million for Q1 2019, and $19.2 million during Q4 2018.